Back to Journals » Drug Design, Development and Therapy » Volume 11

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

Authors López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M

Received 15 December 2016

Accepted for publication 7 March 2017

Published 16 May 2017 Volume 2017:11 Pages 1489—1495

DOI https://doi.org/10.2147/DDDT.S130320

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Rasika Samarasinghe

Peer reviewer comments 5

Editor who approved publication: Dr Anastasios Lymperopoulos

Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6

1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de Málaga, Spain; 2University Children’s Hospital Leipzig, Germany; 3Department of Endocrinology and Reproductive Diseases, Hôpital de Bicêtre, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris and University Paris-Sud, Le Kremlin-Bicêtre, France; 4Clinic of Endocrinology and Diabetology, Children’s Memorial Health Institute, Warsaw, Poland; 5Faculty of Medicine and Health Sciences UJK, Kielce, Poland; 6Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany

Abstract: In 2006, the European Medicines Agency (EMA) approved Omnitrope® as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin®, Pfizer). Data continue to be collected on the long-term efficacy of biosimilar rhGH from several on-going postapproval studies. Particular topics of interest include efficacy in indications granted on the basis of extrapolation, and whether efficacy of growth hormone treatment is affected when patients are changed to biosimilar rhGH from other rhGH products. Data from clinical development studies and 10 years of postapproval experience affirm the clinical efficacy and effectiveness of biosimilar rhGH across all approved indications. In addition, the decade of experience with biosimilar rhGH since it was approved in Europe confirms the scientific validity of the biosimilar pathway and the approval process. Concerns about clinical effect in extrapolated indications, and also about the impact of changing from other rhGH preparations, have been alleviated. Biosimilar rhGH is an effective treatment option for children who require therapy with rhGH.

Keywords: recombinant human growth hormone, Omnitrope®, biosimilar

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

Schiestl M, Zabransky M, Sörgel F

Drug Design, Development and Therapy 2017, 11:1509-1515

Published Date: 16 May 2017

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

Borrás Pérez MV, Kriström B, Romer T, Walczak M, Höbel N, Zabransky M

Drug Design, Development and Therapy 2017, 11:1497-1503

Published Date: 16 May 2017